Ocular Therapeutix™ Reports Second Quarter 2019 Financial Results and Business Update
BEDFORD, Mass.--(BUSINESS WIRE)--<a href="https://twitter.com/search?q=%24OCUL&src=ctag" target="_blank">$OCUL</a> <a href="https://twitter.com/hashtag/OCUTX?src=hash" target="_blank">#OCUTX</a>--Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced financial results for the second quarter ended June 30, 2019 and provided a business update. “It has been a great quarter and productive July for Ocular Therapeutix,” said Antony Mattessich, President and Chief Executive Officer. “We received both our D